Medicare Enrolled
Dr. James Shen, M.D.
Medical Oncology · Arcadia, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shen?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shen
Dr. James Shen is a medical oncology specialist in Arcadia, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Shen performed 140,083 Medicare services across 1,922 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shen received a total of $12,758 from 29 pharmaceutical and/or device companies across 138 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shen is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 3% volume in CA
$12,758 industry payments
Medicare Practice Summary
Medicare Utilization ↗140,083
Medicare services
Top 3% in CA for medical oncology
1,922
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~10,006 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
27,100 | $2 | $11 |
| Nivolumab injection (Opdivo) | 21,000 | $24 | $106 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
17,980 | $0 | $0 |
| Anti-nausea injection (aprepitant) | 15,080 | $1 | $6 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
15,000 | $1 | $4 |
| Denosumab injection (Prolia/Xgeva) | 14,100 | $18 | $83 |
| Pembrolizumab injection (Keytruda) | 11,200 | $43 | $192 |
| Paclitaxel chemotherapy injection | 3,072 | $0 | $0 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
2,615 | $22 | $101 |
| Anti-nausea injection (ondansetron/Zofran) | 1,992 | $0 | $0 |
| Injection, atropine sulfate, 0.01 mg | 1,840 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,786 | $0 | $0 |
| Injection, leucovorin calcium, per 50 mg | 913 | $3 | $14 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
847 | $105 | $481 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
625 | $2 | $8 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
564 | $87 | $390 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
549 | $99 | $431 |
| Injection, irinotecan, 20 mg | 546 | $2 | $8 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
486 | $14 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
347 | $121 | $606 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
317 | $12 | $81 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
223 | $144 | $672 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
188 | $2 | $9 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 168 | $136 | $613 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
129 | $26 | $134 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
123 | $59 | $295 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
122 | $144 | $632 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
115 | $26 | $147 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
84 | $1 | $23 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
79 | $1 | $4 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
76 | $25 | $109 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
71 | $11 | $69 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
69 | $31 | $134 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
69 | $5 | $32 |
| New patient office visit, complex (60-74 min) | 66 | $181 | $821 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
65 | $156 | $448 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
64 | $18 | $84 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
61 | $29 | $220 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
49 | $54 | $269 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
45 | $51 | $247 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
45 | $67 | $306 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
40 | $18 | $88 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
35 | $1 | $5 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
33 | $23 | $103 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
24 | $54 | $341 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 19 | $14 | $62 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
18 | $34 | $200 |
| Prochlorperazine injection, up to 10 mg An injection of prochlorperazine administered in a dose of up to 10 mg. |
17 | $2 | $10 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
15 | $17 | $81 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $57 | $341 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.3% high complexity
87.0% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,758
Total received (2018-2024)
Avg $1,823/year across 7 years
Top 36% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
138
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,112 (71.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,022 (23.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$624 (4.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$475
2023
$35
2022
$284
2021
$3,557
2020
$160
2019
$7,266
2018
$981
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SOBI, INC
$200
GENZYME CORPORATION
$200
Regeneron Healthcare Solutions, Inc.
$31
AstraZeneca Pharmaceuticals LP
$22
Janssen Pharmaceuticals, Inc
$22
Top 3 companies account for 90.7% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$8,935
Amgen Inc.
$753
Seattle Genetics, Inc.
$351
Janssen Biotech, Inc.
$332
E.R. Squibb & Sons, L.L.C.
$292
Astellas Pharma US Inc
$252
Novocure GmbH
$250
GENZYME CORPORATION
$221
Genentech USA, Inc.
$204
SOBI, INC
$200
Merck Sharp & Dohme Corporation
$175
Puma Biotechnology, Inc.
$125
Lilly USA, LLC
$90
Novartis Pharmaceuticals Corporation
$80
Celgene Corporation
$70
PFIZER INC.
$68
MorphoSys, US Inc.
$45
Incyte Corporation
$42
Janssen Pharmaceuticals, Inc
$39
Gilead Sciences, Inc.
$37
Dendreon Pharmaceuticals LLC
$32
Regeneron Healthcare Solutions, Inc.
$31
Exelixis Inc.
$31
JAZZ PHARMACEUTICALS INC.
$24
Mirati Therapeutics, Inc.
$21
Array BioPharma Inc.
$18
EISAI INC.
$16
Foundation Medicine, Inc.
$14
Rigel Pharmaceuticals, Inc.
$12
Top 3 companies account for 78.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Braftovi · CAPRELSA · COSENTYX · Cabometyx · DARZALEX · EMPLICITI · ENHERTU · ERLEADA · EVENITY · Erleada · FOUNDATIONONE · IMFINZI · INREBIC · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · Nerlynx · Neulasta · Nplate · ONUREG · OPDIVO · PADCEV · PROVENGE · Prolia · Revlimid · TAGRISSO · TECENTRIQ · Tavalisse · Trodelvy · VONJO · VYXEOS · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (71%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Medical oncologists within 10 mi
72
Per 100K population
0.7
County median income
$87,760
Nearest hospital
USC ARCADIA HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shen is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with consulting-driven industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shen experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Shen performed 27,100 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shen receive payments from pharmaceutical companies?
Yes. Dr. Shen received a total of $12,758 from 29 companies across 138 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shen's costs compare to other medical oncologists in Arcadia?
Dr. Shen's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Arcadia
Browse medical oncologists in Arcadia ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology